间充质干细胞治疗糖尿病膀胱功能障碍的研究进展  

Research progress of mesenchymal stem cell in the treatment of diabetic bladder dysfunction

作　　者：马聪[1] 程怡钧 肖楠[1] Ma Cong;Cheng Yijun;Xiao Nan(Department of Urology,Lanzhou University Sencond Hospital,Key Laboratory of Gansu Province for Urological Diseases,Gansu Nephro-Urological Clinical Center,Lanzhou 730030,China)

机构地区：[1]兰州大学第二医院泌尿外科,甘肃省泌尿系统疾病研究重点实验室,甘肃省泌尿系统疾病临床医学中心,兰州730030

出　　处：《中华外科杂志》2022年第11期1035-1040,共6页Chinese Journal of Surgery

基　　金：国家自然科学基金(81400760)。

摘　　要：糖尿病膀胱功能障碍(DBD)是糖尿病常见的下尿路并发症。近年来,间充质干细胞(MSC)在DBD治疗中展现出广阔的应用前景。MSC可以迁移到受损的膀胱组织,分化为尿路上皮细胞、肌成纤维细胞、平滑肌细胞和神经细胞等,通过旁分泌效应,促进膀胱组织修复和再生。此外,MSC还通过免疫调节、改善氧化应激和调控血糖等多种途径,干预DBD的病理过程,逆转疾病进展,恢复部分膀胱功能。目前,MSC治疗DBD局限于临床前的动物实验,临床试验与应用尚需进一步研究,其有望成为治疗DBD的新方式。Diabetic bladder dysfunction(DBD)is a common complication in the lower urinary tract of diabetes.In recent years,mesenchymal stem cell(MSC)have broad application prospects in the treatment of DBD.MSC can migrate to damaged bladder tissue and differentiate into various cell types,such as urothelial cells,myofibroblasts,smooth muscle cells and nerve cells,promote bladder tissue repair and regeneration through paracrine effects.In addition,MSC also intervene in the pathological process of DBD,reverse disease progression,and restore partial bladder function through immune regulation,improvement of oxidative stress,and regulation of blood glucose.At present,the treatment of DBD with MSC is limited to preclinical animal experiments,clinical research and application should be pursued further.

关 键 词：糖尿病并发症 膀胱 间质干细胞移植 

分 类 号：R587.2[医药卫生—内分泌] R694[医药卫生—内科学]